NEW YORK (GenomeWeb News) – CML HealthCare today said that it has licensed exclusive rights to offer Mitomics' prostate cancer test in Canada.

The Prostate Core Mitomic Test is a mitochondrial DNA-based test that detects malignant cells in biopsy tissue. The firms said it can detect mitochondrial DNA alterations in benign tissue when a tumor is present in adjacent tissue, and they noted that the test offers 85 percent sensitivity with a negative predictive value of 92 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.